MASERU
The Ministry of Health has introduced a new HIV prevention option, Lenacapavir (LEN), as part of its comprehensive strategy to combat HIV. The introduction of Lenacapavir was announced at a Media awareness Workshop held in Maseru, where journalists were briefed on the importance and details of the new medicine.
HIV and AIDS Communication Expert and Health Promotion Head, Baroane Phenethi, said Lenacapavir is a promising long-acting option that has the potential to change how individuals access and adhere to HIV prevention services. “Lenacapavir has a unique mechanism of action and an extended dosing schedule, which reduces the need for frequent health facility visits,” he explained.
Phenethi highlighted the critical role the media plays in making the public understand health innovations.
“Scientific progress alone is not enough without truthful and responsible reporting,” he said, warning that misinformation can undermine trust, fuel stigma, and slow progress in the fight against HIV. He urged journalists to report on Lenacapavir in a balanced, factual, and stigma-free manner.
Dr. Nthuseng Marake from the HIV and AIDS Programme described Lenacapavir as a highly effective, long-acting Pre-Exposure Prophylaxis(PrEP) that prevents people from being infected with HIV. “Clinical trials have shown strong protection and good safety outcomes,” she said. She further explained that the dosing schedule includes an initiation phase with subcutaneous injections and oral tablets, followed by injections every 26 weeks.
The injection is administered in the abdominal area, and side effects are generally mild to moderate. Dr. Marake clarified that Lenacapavir is not a vaccine and does not cure HIV. “It is a long-acting prevention medicine that works while present in the body, and in some cases may also be used as part of treatment for people living with HIV,” she said.
The Ministry of Health is working to ensure accurate information about Lenacapavir gets to the public. The introduction of Lenacapavir is a significant step in Lesotho’s efforts to strengthen its HIV prevention strategy and promote public health.
Lenacapavir is expected to benefit people who struggle with daily pill regimens or who have difficulty accessing healthcare facilities regularly. The long-acting nature of the medicine is expected to improve adherence to HIV prevention services and reduce the risk of HIV transmission.
The Ministry of Health urges individuals who are at risk of HIV infection to consult with healthcare providers to learn more about Lenacapavir and determine if it is a suitable option for them.
